Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 11 | 2025 | 84 | 2.420 |
Why?
|
| Brain Neoplasms | 12 | 2025 | 312 | 1.360 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 6 | 2018 | 68 | 1.110 |
Why?
|
| Prostatic Neoplasms | 8 | 2014 | 302 | 0.890 |
Why?
|
| Breast Neoplasms | 6 | 2020 | 482 | 0.680 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 360 | 0.650 |
Why?
|
| Radiotherapy, Conformal | 4 | 2012 | 15 | 0.630 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2016 | 130 | 0.620 |
Why?
|
| Radiotherapy Dosage | 14 | 2018 | 107 | 0.610 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2016 | 41 | 0.580 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2014 | 481 | 0.570 |
Why?
|
| Radiation Dosage | 2 | 2015 | 54 | 0.560 |
Why?
|
| Trigeminal Neuralgia | 1 | 2018 | 13 | 0.560 |
Why?
|
| Aged, 80 and over | 12 | 2018 | 2065 | 0.540 |
Why?
|
| Fiducial Markers | 1 | 2016 | 1 | 0.500 |
Why?
|
| Patient Positioning | 2 | 2016 | 23 | 0.490 |
Why?
|
| Aged | 20 | 2019 | 5598 | 0.480 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 36 | 0.480 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2015 | 27 | 0.450 |
Why?
|
| Rib Fractures | 1 | 2015 | 4 | 0.450 |
Why?
|
| Radiation Injuries | 1 | 2015 | 52 | 0.440 |
Why?
|
| Middle Aged | 20 | 2019 | 7414 | 0.420 |
Why?
|
| Tumor Burden | 1 | 2014 | 110 | 0.410 |
Why?
|
| Hippocampus | 1 | 2015 | 198 | 0.410 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 105 | 0.380 |
Why?
|
| Humans | 45 | 2025 | 28851 | 0.380 |
Why?
|
| Retrospective Studies | 11 | 2020 | 2635 | 0.370 |
Why?
|
| Brachytherapy | 5 | 2013 | 54 | 0.360 |
Why?
|
| Adult | 17 | 2019 | 8024 | 0.330 |
Why?
|
| Sensitivity and Specificity | 6 | 2015 | 524 | 0.330 |
Why?
|
| Male | 24 | 2019 | 13921 | 0.300 |
Why?
|
| Reproducibility of Results | 5 | 2015 | 787 | 0.300 |
Why?
|
| Female | 24 | 2020 | 15624 | 0.290 |
Why?
|
| Radiometry | 3 | 2014 | 45 | 0.260 |
Why?
|
| Motion | 3 | 2016 | 27 | 0.240 |
Why?
|
| Prostate | 2 | 1996 | 52 | 0.240 |
Why?
|
| Adenocarcinoma | 2 | 2000 | 300 | 0.230 |
Why?
|
| Radiographic Image Enhancement | 2 | 2016 | 28 | 0.230 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2016 | 58 | 0.220 |
Why?
|
| Models, Statistical | 2 | 2016 | 128 | 0.210 |
Why?
|
| Re-Irradiation | 1 | 2022 | 2 | 0.190 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 480 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2020 | 63 | 0.190 |
Why?
|
| Prostate-Specific Antigen | 2 | 2000 | 53 | 0.190 |
Why?
|
| Treatment Outcome | 5 | 2015 | 2426 | 0.180 |
Why?
|
| Phantoms, Imaging | 4 | 2016 | 101 | 0.180 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2015 | 37 | 0.180 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2015 | 107 | 0.180 |
Why?
|
| Glioblastoma | 1 | 2022 | 109 | 0.180 |
Why?
|
| Laser Therapy | 1 | 2020 | 30 | 0.160 |
Why?
|
| Hyperthermia, Induced | 1 | 2000 | 30 | 0.160 |
Why?
|
| Brain Edema | 1 | 2019 | 21 | 0.150 |
Why?
|
| Uncertainty | 2 | 2016 | 25 | 0.150 |
Why?
|
| Melanoma | 2 | 2020 | 140 | 0.150 |
Why?
|
| Survival Rate | 2 | 2017 | 432 | 0.140 |
Why?
|
| Meningeal Neoplasms | 1 | 2019 | 73 | 0.140 |
Why?
|
| Meningioma | 1 | 2019 | 79 | 0.140 |
Why?
|
| Prone Position | 1 | 1998 | 5 | 0.140 |
Why?
|
| Carcinoma | 1 | 1999 | 74 | 0.140 |
Why?
|
| Mastectomy, Segmental | 3 | 2020 | 20 | 0.140 |
Why?
|
| Cognition | 2 | 1999 | 331 | 0.140 |
Why?
|
| Combined Modality Therapy | 6 | 2010 | 303 | 0.140 |
Why?
|
| Sex Characteristics | 2 | 1999 | 173 | 0.130 |
Why?
|
| Visual Cortex | 1 | 1997 | 8 | 0.130 |
Why?
|
| Macaca mulatta | 1 | 1997 | 50 | 0.130 |
Why?
|
| Prospective Studies | 5 | 2022 | 1280 | 0.130 |
Why?
|
| Age Factors | 2 | 2016 | 737 | 0.130 |
Why?
|
| Smoking | 2 | 1999 | 477 | 0.130 |
Why?
|
| Craniotomy | 1 | 2017 | 61 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 1996 | 34 | 0.130 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2016 | 5 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 433 | 0.120 |
Why?
|
| Thoracic Wall | 1 | 2015 | 11 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 1995 | 33 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 2 | 2014 | 93 | 0.110 |
Why?
|
| Chest Pain | 1 | 2015 | 26 | 0.110 |
Why?
|
| Neurons | 1 | 1997 | 297 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 79 | 0.110 |
Why?
|
| Endometrial Neoplasms | 1 | 1996 | 189 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 1032 | 0.110 |
Why?
|
| Genital Neoplasms, Female | 1 | 2015 | 67 | 0.110 |
Why?
|
| Young Adult | 3 | 2019 | 2833 | 0.110 |
Why?
|
| Respiratory Mechanics | 1 | 2014 | 17 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2014 | 6 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 74 | 0.110 |
Why?
|
| Algorithms | 2 | 2014 | 431 | 0.110 |
Why?
|
| Palliative Care | 1 | 2015 | 86 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 100 | 0.110 |
Why?
|
| Artifacts | 1 | 2014 | 51 | 0.100 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 39 | 0.100 |
Why?
|
| Immobilization | 2 | 2010 | 15 | 0.100 |
Why?
|
| Treatment Failure | 3 | 2019 | 73 | 0.100 |
Why?
|
| Iodine Radioisotopes | 1 | 2013 | 36 | 0.100 |
Why?
|
| Apoptosis | 1 | 1996 | 780 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1995 | 841 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 15 | 0.090 |
Why?
|
| Orbital Pseudotumor | 1 | 2010 | 2 | 0.090 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2011 | 14 | 0.080 |
Why?
|
| Head | 1 | 2010 | 19 | 0.080 |
Why?
|
| Monte Carlo Method | 1 | 2010 | 62 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2010 | 41 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 70 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2009 | 243 | 0.070 |
Why?
|
| Prognosis | 3 | 2015 | 811 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 347 | 0.070 |
Why?
|
| Breast | 2 | 2020 | 52 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2002 | 288 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 1996 | 302 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2003 | 27 | 0.060 |
Why?
|
| Risk Factors | 3 | 2019 | 2126 | 0.050 |
Why?
|
| Lymphoma, T-Cell | 1 | 2003 | 8 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2022 | 106 | 0.050 |
Why?
|
| Adolescent | 4 | 2019 | 3193 | 0.050 |
Why?
|
| Intraoperative Care | 1 | 2020 | 23 | 0.040 |
Why?
|
| Lasers | 1 | 2020 | 68 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 1999 | 236 | 0.040 |
Why?
|
| Galvanic Skin Response | 1 | 1999 | 20 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 1999 | 72 | 0.040 |
Why?
|
| Heart Rate | 1 | 1999 | 382 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 1997 | 69 | 0.030 |
Why?
|
| Geniculate Bodies | 1 | 1997 | 3 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 477 | 0.030 |
Why?
|
| Cell Size | 1 | 1997 | 25 | 0.030 |
Why?
|
| Visual Pathways | 1 | 1997 | 17 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1997 | 94 | 0.030 |
Why?
|
| Cell Count | 1 | 1997 | 86 | 0.030 |
Why?
|
| Nicotine | 1 | 1997 | 86 | 0.030 |
Why?
|
| Cesium Radioisotopes | 1 | 1996 | 4 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1996 | 5 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1997 | 391 | 0.030 |
Why?
|
| Gestational Age | 1 | 1997 | 147 | 0.030 |
Why?
|
| Cell Communication | 1 | 1997 | 68 | 0.030 |
Why?
|
| Gamma Rays | 1 | 1996 | 27 | 0.030 |
Why?
|
| Lymphoma | 1 | 1996 | 26 | 0.030 |
Why?
|
| Bronchiectasis | 1 | 1996 | 3 | 0.030 |
Why?
|
| Respiratory Sounds | 1 | 1996 | 6 | 0.030 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1996 | 16 | 0.030 |
Why?
|
| Seminal Vesicles | 1 | 1995 | 5 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1996 | 314 | 0.030 |
Why?
|
| Urethra | 1 | 1995 | 33 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 1999 | 415 | 0.030 |
Why?
|
| Mitomycin | 1 | 1995 | 19 | 0.030 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1997 | 136 | 0.030 |
Why?
|
| Kinetics | 1 | 1996 | 553 | 0.030 |
Why?
|
| Fluorouracil | 1 | 1995 | 58 | 0.030 |
Why?
|
| Asthma | 1 | 1996 | 60 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 1996 | 122 | 0.030 |
Why?
|
| Hospice Care | 1 | 2015 | 16 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 51 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 194 | 0.030 |
Why?
|
| Cell Line | 1 | 1996 | 700 | 0.030 |
Why?
|
| Vitrectomy | 1 | 1993 | 8 | 0.030 |
Why?
|
| Radioisotopes | 1 | 2013 | 11 | 0.020 |
Why?
|
| Palladium | 1 | 2013 | 9 | 0.020 |
Why?
|
| Seeds | 1 | 2013 | 14 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 232 | 0.020 |
Why?
|
| Edema | 1 | 2013 | 18 | 0.020 |
Why?
|
| Pregnancy | 1 | 1997 | 1254 | 0.020 |
Why?
|
| Remission Induction | 2 | 2003 | 58 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 1991 | 14 | 0.020 |
Why?
|
| Particle Accelerators | 1 | 2011 | 5 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 13 | 0.020 |
Why?
|
| Electronics | 1 | 2010 | 4 | 0.020 |
Why?
|
| Safety | 1 | 2010 | 32 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 75 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 21 | 0.020 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2010 | 4 | 0.020 |
Why?
|
| Radiation Monitoring | 1 | 2010 | 8 | 0.020 |
Why?
|
| Radiography | 1 | 2010 | 203 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 134 | 0.020 |
Why?
|
| Prosthesis Implantation | 1 | 2009 | 26 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2009 | 28 | 0.020 |
Why?
|
| Glucose | 1 | 1991 | 209 | 0.020 |
Why?
|
| Cerebral Arterial Diseases | 1 | 1969 | 2 | 0.020 |
Why?
|
| Spirometry | 2 | 1966 | 10 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 1969 | 79 | 0.020 |
Why?
|
| Nicotinic Acids | 1 | 1968 | 2 | 0.020 |
Why?
|
| Amino Alcohols | 1 | 1968 | 3 | 0.020 |
Why?
|
| Skin | 1 | 2010 | 152 | 0.020 |
Why?
|
| Varicose Veins | 1 | 1968 | 3 | 0.020 |
Why?
|
| Blood Circulation | 1 | 1968 | 13 | 0.020 |
Why?
|
| Dipyridamole | 1 | 1967 | 1 | 0.020 |
Why?
|
| Oxazepam | 1 | 1967 | 1 | 0.020 |
Why?
|
| Oklahoma | 1 | 2011 | 1052 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 1969 | 224 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1967 | 30 | 0.020 |
Why?
|
| Niacinamide | 1 | 1967 | 32 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 1967 | 109 | 0.020 |
Why?
|
| Expectorants | 1 | 1966 | 1 | 0.020 |
Why?
|
| Auscultation | 1 | 1966 | 3 | 0.020 |
Why?
|
| Bronchial Diseases | 1 | 1966 | 5 | 0.020 |
Why?
|
| Pyridines | 1 | 1967 | 108 | 0.020 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2003 | 2 | 0.010 |
Why?
|
| Animals | 1 | 1997 | 10684 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2003 | 61 | 0.010 |
Why?
|
| Space Perception | 1 | 1999 | 9 | 0.010 |
Why?
|
| Arousal | 1 | 1999 | 38 | 0.010 |
Why?
|
| Rheology | 2 | 1969 | 22 | 0.010 |
Why?
|
| Vital Capacity | 1 | 1996 | 7 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 1996 | 16 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 1996 | 17 | 0.010 |
Why?
|
| Heart Function Tests | 2 | 1967 | 10 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1996 | 379 | 0.010 |
Why?
|
| Electrocardiography | 2 | 1968 | 398 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1996 | 485 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 1999 | 415 | 0.010 |
Why?
|
| Retinal Detachment | 1 | 1993 | 11 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1993 | 31 | 0.010 |
Why?
|
| Child | 1 | 1999 | 2287 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1991 | 6 | 0.010 |
Why?
|
| Deoxyglucose | 1 | 1991 | 9 | 0.010 |
Why?
|
| Fluorine Radioisotopes | 1 | 1991 | 26 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1991 | 79 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1991 | 103 | 0.010 |
Why?
|
| Glioma | 1 | 1991 | 122 | 0.000 |
Why?
|
| Mandelic Acids | 1 | 1969 | 2 | 0.000 |
Why?
|
| Blood Volume | 1 | 1969 | 8 | 0.000 |
Why?
|
| Blood Pressure Determination | 1 | 1967 | 27 | 0.000 |
Why?
|
| Convalescence | 1 | 1964 | 6 | 0.000 |
Why?
|
| Rehabilitation | 1 | 1964 | 4 | 0.000 |
Why?
|
| Myocardial Infarction | 1 | 1964 | 351 | 0.000 |
Why?
|